Mounjaro®▼ (tirzepatide) 2.5 mg KwikPen® – shelf-life extension

Based on Lilly’s submission of additional stability data, the MHRA have approved an extension to the shelf-life of the following batches of Mounjaro®▼ (tirzepatide) 2.5mg KwikPen®:

To help ensure patient clarity on the new expiry date, product from these batches still under Lilly’s control will be packed with a “Dear Patient Letter” explaining the expiry date extension. Product already released to the market can be used until the new expiration dates above.

Additional details can be found in the “Dear HCP Letter” and “Dear Patient Letters” – there are 2 different patient letters, based on the relevant expiry date of the specific batch D712074 and D720751/D720957.

This medicine is subject to additional monitoring.  This includes any possible side effects not listed in the package leaflet.  This will allow quick identification of new safety information.  You can help by reporting any side effects you may get, see www.mhra.gov.uk/yellowcard.